Five-Year Outcomes of Transcatheter or Surgical Aortic-Valve Replacement.

Journal Article (Journal Article;Multicenter Study)

BACKGROUND: There are scant data on long-term clinical outcomes and bioprosthetic-valve function after transcatheter aortic-valve replacement (TAVR) as compared with surgical aortic-valve replacement in patients with severe aortic stenosis and intermediate surgical risk. METHODS: We enrolled 2032 intermediate-risk patients with severe, symptomatic aortic stenosis at 57 centers. Patients were stratified according to intended transfemoral or transthoracic access (76.3% and 23.7%, respectively) and were randomly assigned to undergo either TAVR or surgical replacement. Clinical, echocardiographic, and health-status outcomes were followed for 5 years. The primary end point was death from any cause or disabling stroke. RESULTS: At 5 years, there was no significant difference in the incidence of death from any cause or disabling stroke between the TAVR group and the surgery group (47.9% and 43.4%, respectively; hazard ratio, 1.09; 95% confidence interval [CI], 0.95 to 1.25; P = 0.21). Results were similar for the transfemoral-access cohort (44.5% and 42.0%, respectively; hazard ratio, 1.02; 95% CI, 0.87 to 1.20), but the incidence of death or disabling stroke was higher after TAVR than after surgery in the transthoracic-access cohort (59.3% vs. 48.3%; hazard ratio, 1.32; 95% CI, 1.02 to 1.71). At 5 years, more patients in the TAVR group than in the surgery group had at least mild paravalvular aortic regurgitation (33.3% vs. 6.3%). Repeat hospitalizations were more frequent after TAVR than after surgery (33.3% vs. 25.2%), as were aortic-valve reinterventions (3.2% vs. 0.8%). Improvement in health status at 5 years was similar for TAVR and surgery. CONCLUSIONS: Among patients with aortic stenosis who were at intermediate surgical risk, there was no significant difference in the incidence of death or disabling stroke at 5 years after TAVR as compared with surgical aortic-valve replacement. (Funded by Edwards Lifesciences; PARTNER 2 number, NCT01314313.).

Full Text

Duke Authors

Cited Authors

  • Makkar, RR; Thourani, VH; Mack, MJ; Kodali, SK; Kapadia, S; Webb, JG; Yoon, S-H; Trento, A; Svensson, LG; Herrmann, HC; Szeto, WY; Miller, DC; Satler, L; Cohen, DJ; Dewey, TM; Babaliaros, V; Williams, MR; Kereiakes, DJ; Zajarias, A; Greason, KL; Whisenant, BK; Hodson, RW; Brown, DL; Fearon, WF; Russo, MJ; Pibarot, P; Hahn, RT; Jaber, WA; Rogers, E; Xu, K; Wheeler, J; Alu, MC; Smith, CR; Leon, MB; PARTNER 2 Investigators,

Published Date

  • February 27, 2020

Published In

Volume / Issue

  • 382 / 9

Start / End Page

  • 799 - 809

PubMed ID

  • 31995682

Electronic International Standard Serial Number (EISSN)

  • 1533-4406

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1910555


  • eng

Conference Location

  • United States